Ph.D. WEI-WU HE - 13 Jun 2022 Form 4 Insider Report for CASI Pharmaceuticals, Inc.

Role
Chairman and CEO, Director, 10%+ Owner
Signature
/s/ Alexander Zukiwski, attorney-in-fact for Wei-Wu He
Issuer symbol
N/A
Transactions as of
13 Jun 2022
Net transactions value
+$272,506
Form type
4
Filing time
17 Jun 2022, 16:14:02 UTC
Previous filing
19 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CASI Common Stock Purchase $107,092 +36,058 +6.5% $2.97* 592,457 13 Jun 2022 Direct F1, F2
transaction CASI Common Stock Purchase $6,414 +2,096 +0.35% $3.06* 594,553 14 Jun 2022 Direct F1, F2
transaction CASI Common Stock Purchase $159,000 +50,000 +8.4% $3.18* 644,553 15 Jun 2022 Direct F1, F2
holding CASI Common Stock 300,000 13 Jun 2022 See Footnote F2, F3
holding CASI Common Stock 753,234 13 Jun 2022 See Footnote F2, F4
holding CASI Common Stock 44,107 13 Jun 2022 See Footnote F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.08 to $3.20 per share on June 15, 2022, $3.04 to $3.06 per share on June 14, 2022, and $2.87 to $3.00 per share on June 13, 2022. The Reporting Person undertakes to provide to the issuer, or any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 On June 1, 2022, the Issuer effected a 1-for-10 reverse stock split (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F3 The shares are held indirectly in the name of ETP BioHealth III Fund, LP, a limited partnership of which the Reporting Person is the managing member of the general partner. The Reporting Person disclaims beneficial ownership over any shares held indirectly, except to the extent of his pecuniary interest therein and his filing is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or any other purposes.
F4 The shares are held indirectly in the name of ETP Global Fund LP, a limited partnership of which the Reporting Person is the managing member of the general partner. The Reporting Person disclaims beneficial ownership over any shares held indirectly, except to the extent of his pecuniary interest therein and his filing is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or any other purposes.
F5 The shares are held indirectly in the name of Emerging Technology Partners, LLC, an LLC entity of which the Reporting Person is the managing member. The Reporting Person disclaims beneficial ownership over any shares held indirectly, except to the extent of his pecuniary interest thein and his filing is not an admission that the Reporting Person is the beneficial owner of these shares for the purposes of Section 16 or any other purposes.

Remarks:

Exhibit 24 - Power of Attorney